Nutrigenomics: Where are we with genetic and epigenetic markers for disposition and susceptibility?

Nutrition Reviews

Volumn 68, Issue SUPPL. 1, 2010, Pages

  Kussmann, Martin ^a,b   Krause, Lutz ^a   Siffert, Winfried ^c  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Biomarker; Brain; Cognition; Epigenetics; Nutrigenetics; Nutrigenomics

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; UNTRANSLATED RNA;

ARTICLE; ATHEROSCLEROSIS; BRAIN DEVELOPMENT; CHROMATIN STRUCTURE; COGNITION; DISEASE PREDISPOSITION; DNA METHYLATION; DNA SEQUENCE; DYSPEPSIA; EPIGENETICS; GENETIC MARKER; HISTONE CODE; HUMAN; HYPERTENSION; IRRITABLE COLON; METABOLIC SYNDROME X; NUTRIGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT REDUCTION;

BRAIN; BRAIN DISEASES; COGNITION; EPIGENOMICS; GENETIC MARKERS; HUMANS; NUTRIGENOMICS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA;

EID: 77958473397     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2010.00326.x     Document Type: Article

References (94)

1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome [Review]. Nature. 2001;409:860-921.
2. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome [Review]. Science. 2001;291:1304-1351.
3. Kussmann M, Rezzi S, Daniel H. Profiling techniques in nutrition and health research. Curr Opin Biotechnol. 2008;19:83-99.
4. Kussmann M, Raymond F, Affolter M. OMICS-driven biomarker discovery in nutrition and health. J Biotechnol. 2006;124:758-787.
5. Manolio TA. Cohort studies and the genetics of complex disease. Nat Genet. 2009;41:5-6.
6. Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med. 2005;56:17-28.
7. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220-2232.
8. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208-2219.
9. Maher B. Personal genomes: the case of the missing heritability. Nature. 2008;456:18-21.
10. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316:1336-1341.
11. Blow N. Genomics: the personal side of genomics. Nature. 2007;449:627-630.
12. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31:89-97.
13. Talbert PB, Henikoff S. Spreading of silent chromatin: inaction at a distance. Nat Rev Genet. 2006;7:793-803.
14. Briggs SD, Xiao T, Sun ZW, et al. Gene silencing: trans-histone regulatory pathway in chromatin. Nature. 2002;418:498.
15. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811.
16. Reik W, Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet. 2001;2:21-32.
17. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41-45.
18. Zhao XJ, Li C, Paez JG, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res. 2004;64:3060-3071.
19. Nelson MR, Marnellos G, Kammerer S, et al. Large-scale validation of single nucleotide polymorphisms in gene regions. Genome Res. 2004;14:1664-1668.
20. Bourne HR. How receptors talk to trimeric G proteins. Curr Opin Cell Biol. 1997;9:134-142.
21. Downes GB, Gautam N. The G protein subunit gene families. Genomics. 1999;62:544-552.
22. Gautam N, Downes GB, Yan K, Kisselev O. The G-protein betagamma complex. Cell Signal. 1998;10:447-455.
23. Frey UH, Hauner H, Jockel KH, Manthey I, Brockmeyer N, Siffert W. A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation. Pharmacogenet Genomics. 2008;18:141-151.
24. Gutersohn A, Naber C, Muller N, Erbel R, Siffert W. G protein beta3 subunit 825 TT genotype and post-pregnancy weight retention. Lancet. 2000;355:1240-1241.
25. Hauner H, Meier M, Jockel KH, Frey UH, Siffert W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics. 2003;13:453-459.
26. Holtmann G, Siffert W, Haag S, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology. 2004;126:971-979.
27. Mitchell A, Rushentsova U, Siffert W, Philipp T, Wenzel RR. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism. Clin Pharmacol Ther. 2006;79:274-281.
28. Nurnberger J, Dammer S, Mitchell A, et al. Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Ther. 2003;74:53-60.
29. Wenzel RR, Siffert W, Bruck H, Philipp T, Schafers RF. Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. Pharmacogenetics. 2002;12:489-495.
30. Siffert W, Forster P, Jockel KH, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol. 1999;10:1921-1930.
31. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007;8:253-262.
32. Huynh KD, Lee JT. X-chromosome inactivation: a hypothesis linking ontogeny and phylogeny. Nat Rev Genet. 2005;6:410-418.
33. Falls JG, Pulford DJ, Wylie AA, Jirtle RL. Genomic imprinting: implications for human disease. Am J Pathol. 1999;154:635-647.
34. Slotkin RK, Martienssen R. Transposable elements and the epigenetic regulation of the genome. Nat Rev Genet. 2007;8:272-285.
35. Jirtle RL. Randy L. Jirtle, PhD: epigenetics a window on gene dysregulation, disease. Interview by Bridget M. Kuehn. JAMA. 2008;299:1249-1250.
36. Gluckman PD, Hanson MA, Buklijas T, Low FM, Beedle AS. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol. 2009;5:401-408.
37. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102:10604-10609.
38. Painter RC, Roseboom TJ, Bleker OP. Prenatal exposure to the Dutch famine and disease in later life: an overview. Reprod Toxicol. 2005;20:345-352.
39. Yajnik CS. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. J Nutr. 2004;134:205-210.
40. Singhal A. Early nutrition and long-term cardiovascular health. Nutr Rev. 2006;64:S44-S49.
41. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115:e290-e296.
42. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35:595-601.
43. Osmond C, Barker DJ, Winter PD, Fall CH, Simmonds SJ. Early growth and death from cardiovascular disease in women. BMJ. 1993;307:1519-1524.
44. Kuzawa CW, Adair LS. Lipid profiles in adolescent Filipinos: relation to birth weight and maternal energy status during pregnancy. Am J Clin Nutr. 2003;77:960-966.
45. Sinclair KD, Allegrucci C, Singh R, et al. DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci U S A. 2007;104:19351-19356.
46. Heijmans BT, Tobi EW, Stein AD, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008;105:17046-17049.
47. Nafee TM, Farrell WE, Carroll WD, Fryer AA, Ismail KM. Epigenetic control of fetal gene expression. BJOG. 2008;115:158-168.
48. Vickers MH, Breier BH, Cutfield WS, Hofman PL, Gluckman PD. Fetal origins of hyperphagia, obesity, and hypertension and postnatal amplification by hypercaloric nutrition. Am J Physiol Endocrinol Metab. 2000;279:E83-E87.
49. Schaefer-Graf UM, Pawliczak J, Passow D, et al. Birth weight and parental BMI predict overweight in children from mothers with gestational diabetes. Diabetes Care. 2005;28:1745-1750.
50. Aagaard-Tillery KM, Grove K, Bishop J, et al. Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome. J Mol Endocrinol. 2008;41:91-102.
51. Waterland RA, Lin JR, Smith CA, Jirtle RL. Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus. Hum Mol Genet. 2006;15:705-716.
52. Gluckman PD, Lillycrop KA, Vickers MH, et al. Metabolic plasticity during mammalian development is directionally dependent on early nutritional status. Proc Natl Acad Sci U S A. 2007;104:12796-12800.
53. Robinson SM, Crozier SR, Borland SE, Hammond J, Barker DJ, Inskip HM. Impact of educational attainment on the quality of young women's diets. Eur J Clin Nutr. 2004;58:1174-1180.
54. Yajnik CS, Deshpande SS, Jackson AA, et al. Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia. 2008;51:29-38.
55. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr. 2005;135:1382-1386.
56. Vickers MH, Gluckman PD, Coveny AH, et al. Neonatal leptin treatment reverses developmental programming. Endocrinology. 2005;146:4211-4216.
57. Lawlor DA, Smith GD, O'Callaghan M, et al. Epidemiologic evidence for the fetal overnutrition hypothesis: findings from the mater university study of pregnancy and its outcomes. Am J Epidemiol. 2007;165:418-424.
58. Waterland RA, Travisano M, Tahiliani KG, Rached MT, Mirza S. Methyl donor supplementation prevents transgenerational amplification of obesity. Int J Obes (Lond). 2008;32:1373-1379.
59. Park JH, Stoffers DA, Nicholls RD, Simmons RA. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest. 2008;118:2316-2324.
60. McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev. 2005;85:571-633.
61. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763-770.
62. Yokomori N, Tawata M, Onaya T. DNA demethylation modulates mouse leptin promoter activity during the differentiation of 3T3-L1 cells. Diabetologia. 2002;45:140-148.
63. Melzner I, Scott V, Dorsch K, et al. Leptin gene expression in human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its proximal promoter. J Biol Chem. 2002;277:45420-45427.
64. Antequera F, Boyes J, Bird A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell. 1990;62:503-514.
65. Rankinen T, Zuberi A, Chagnon YC, et al. The human obesity gene map: the 2005 update. Obesity (Silver Spring). 2006;14:529-644.
66. Ordovas JM, Corella D. Nutritional genomics. Annu Rev Genomics Hum Genet. 2004;5:71-118.
67. Ordovas JM, Mooser V. Nutrigenomics and nutrigenetics. Curr Opin Lipidol. 2004;15:101-108.
68. Kaput J. Nutrigenomics research for personalized nutrition and medicine. Curr Opin Biotechnol. 2008;19:110-120.
69. Pearce MS, Deary IJ, Young AH, Parker L. Growth in early life and childhood IQ at age 11 years: the Newcastle Thousand Families Study. Int J Epidemiol. 2005;34:673-677.
70. Feart C, Samieri C, Barberger-Gateau P. Mediterranean diet and cognitive function in older adults. Curr Opin Clin Nutr Metab Care. 2009.
71. Le Coutre J, Schmitt JA. Food ingredients and cognitive performance. Curr Opin Clin Nutr Metab Care. 2008;11:706-710.
72. Nokelainen P, Flint J. Genetic effects on human cognition: lessons from the study of mental retardation syndromes. J Neurol Neurosurg Psychiatry. 2002;72:287-296.
73. Francks C, Fisher SE, Marlow AJ, et al. Familial and genetic effects on motor coordination, laterality, and reading-related cognition. Am J Psychiatry. 2003;160:1970-1977.
74. Latourelle JC, Pankratz N, Dumitriu A, et al. Genomewide association study for onset age in Parkinson disease. BMC Med Genet. 2009;10:98.
75. Levi RS, Sanderson IR. Dietary regulation of gene expression. Curr Opin Gastroenterol. 2004;20:139-142.
76. Pinsonneault JK, Papp AC, Sadee W. Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain: dissection of epigenetic and genetic factors. Hum Mol Genet. 2006;15:2636-2649.
77. Hogart A, Nagarajan RP, Patzel KA, Yasui DH, Lasalle JM. 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum Mol Genet. 2007;16:691-703.
78. Kalueff AV. Neurobiology of memory and anxiety: from genes to behavior. Neural Plast. 2007;2007:78171.
79. Burmeister M, McInnis MG, Zollner S. Psychiatric genetics: progress amid controversy. Nat Rev Genet. 2008;9:527-540.
80. Pearson JV, Huentelman MJ, Halperin RF, et al. Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet. 2007;80:126-139.
81. Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics, and proteomics of Alzheimer's disease. J Clin Psychiatry. 2006;67(4):652-670.
82. Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset-Alzheimer's disease. J Clin Psychiatry. 2007;68:613-618.
83. Papassotiropoulos A, Henke K, Stefanova E, et al. A genome-wide survey of human short-term memory. Mol Psychiatry. Advance online publication, 29 December 2009:doi: 10.1038/mp.2009.133.
84. Papassotiropoulos A, Stephan DA, Huentelman MJ, et al. Common Kibra alleles are associated with human memory performance. Science. 2006;314:475-478.
85. Mondadori CR, De Quervain DJ, Buchmann A, et al. Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb Cortex. 2007;17:1934-1947.
86. De Quervain DJ, Papassotiropoulos A. Identification of a genetic cluster influencing memory performance and hippocampal activity in humans. Proc Natl Acad Sci U S A. 2006;103:4270-4274.
87. Huentelman MJ, Papassotiropoulos A, Craig DW, et al. Calmodulin-binding transcription activator 1 (CAMTA1) alleles predispose human episodic memory performance. Hum Mol Genet. 2007;16:1469-1477.
88. De Quervain DJ, Kolassa IT, Ertl V, et al. A deletion variant of the alpha2b-adrenoceptor is related to emotional memory in Europeans and Africans. Nat Neurosci. 2007;10:1137-1139.
89. Rasch B, Spalek K, Buholzer S, et al. A genetic variation of the noradrenergic system is related to differential amygdala activation during encoding of emotional memories. Proc Natl Acad Sci U S A. 2009;106:19191-19196.
90. Payton A, Gibbons L, Davidson Y, et al. Influence of serotonin transporter gene polymorphisms on cognitive decline and cognitive abilities in a nondemented elderly population. Mol Psychiatry. 2005;10:1133-1139.
91. Need AC, Attix DK, McEvoy JM, et-al. A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum Mol Genet. 2009;18:4650-4661.
92. Zappaterra MD, Lisgo SN, Lindsay S, Gygi SP, Walsh CA, Ballif BA. A comparative proteomic analysis of human and rat embryonic cerebrospinal fluid. J-Proteome-Res. 2007;6:3537-3548.
93. Khwaja FW, Nolen JDL, Mendrinos SE, et al. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics Dec. 2006;6:6277-6287.
94. Firmann M, Mayor V, Vidal PM, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6.